Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.65 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.65 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.65 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | AMY2A | P04746 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084197 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL10068129 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL13541588 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL15962542 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL12733135 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL24770581 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL18383019 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL18387251 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL22193219 | 1.00 | LGALS3 (0.65) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL23059762 | 0.98 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304998-A1 | CELLULAR MATERIAL DETECTION PROBES | FluoretiQ Limited (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11214588-B2 | Synthesis of oligosaccharides | GLYCOM A/S (DK) | 2022-01-04 | — | — | US | disclosed |
| US-20210308162-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-07 | — | — | US | disclosed |
| US-10933077-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200215486-A1 | SYNTHESIS OF OLIGOSACCHARIDES | GLYCOM A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20120070382-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070382-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214588-B2 | Synthesis of oligosaccharides | MGAM, LCT, LPO | LGALS3 969/4885LGALS8 348/4885LGALS4 577/4885 |
| US-20210308162-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LGALS3 487/4885LGALS8 431/4885LGALS4 203/4885 |
| US-20120070382-A1 | FLUORESCENT CONJUGATED POLYMERS WITH A BODIPY-BASED BACKBONE AND USES THEREOF | TLR3, TLR5, PARP15 | LGALS3 399/4885LGALS8 1606/4885LGALS4 524/4885 |
| US-10933077-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | TLR4, TLR3, TLR1 | LGALS3 492/4885LGALS8 505/4885LGALS4 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.